Co-inhibition of EGFR and ANO1 had an additive effect on head and neck cancer cell proliferation, suggesting that co-targeting of ANO1 and EGFR could enhance the clinical potential of EGFR-targeted therapy in HNSCC and might delay or prevent resistance to single agent treatment. Here, ANO1 is linked to head and neck cancer.